Eczema (Atopic Dermatitis) Clinical Trials in Seattle
View 23 new treatments for Eczema (Atopic Dermatitis) in Seattle, WA, and nearby areas, such as Bellevue, Everett, Kent and Renton. Every day, Power helps hundreds of eczema patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Amlitelimab + Topical Corticosteroids for Atopic Dermatitis (AQUA)
Sanofi Clinic, Mill Creek + 1 more
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy. Study details include: At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD). The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 [RIVER-AD]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 [RIVER-AD]) including a 2 to 4-week screening and a 36-week randomized double-blind period. The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 [RIVER-AD] study).Show More
Verified
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Nemolizumab for Eczema
Galderma Clinic, Seattle + 1 more
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Waitlist
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Upadacitinib + Topical Corticosteroids for Eczema
AbbVie Clinic, Seattle + 1 more
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
ABBVIE INC.
Study Director
Rocatinlimab for Eczema
Amgen Clinic, Mill Creek + 1 more
This trial is testing a new medication called rocatinlimab to see if it works well and is safe when used alone. It targets patients who might benefit from a new treatment option.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
MD
Study Director
Abrocitinib for Atopic Dermatitis/Eczema
Pfizer Clinic, Tacoma + 6 more
This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Pfizer CT.gov Call Center
Study Director
Lebrikizumab for Eczema
Eli Lilly Clinic, Seattle + 2 more
This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Rocatinlimab for Atopic Dermatitis
Amgen Clinic, Bellevue + 1 more
This trial is testing a medication called rocatinlimab to see if it works and is safe for teenagers. The medication can be used by itself or with other treatments. It aims to help by interacting with the immune system.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
MD
Study Director
Povorcitinib for Prurigo Nodularis
Incyte Clinic, Mill Creek + 2 more
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Recruiting
Phase 3
Est. 3 - 6 Weeks
Incyte Medical Monitor
Study Director
Povorcitinib for Prurigo Nodularis
Incyte Clinic, Seattle + 1 more
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Recruiting
Phase 3
Est. 6 - 12 Weeks
Incyte Medical Monitor
Study Director
Ruxolitinib Cream for Eczema
Incyte Clinic, Mill Creek + 1 more
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Incyte Medical Monitor
Study Director
Page 1 of 2
Frequently Asked Questions
Explore related conditions